# SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

> **NCT03161431** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Syntrix Biosystems, Inc.** · enrollment: 77 (estimated)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV

## Interventions

- **DRUG:** SX-682
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03161431
- **Lead sponsor:** Syntrix Biosystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-12
- **Primary completion:** 2026-08
- **Final completion:** 2027-06
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161431, "SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03161431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*